Exercise

Studies of exercise in people

1,238 studies gave exercise to people and measured what changed

What changedDesignPeopleSource

down: Decreases FGF23

Trial24 h10 peopleWomenpremenopausalFollowing resistance or interval-running exerciseApplied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme, Nov 16, 2026

no change: Has no effect on food-related ERP responsesInteraction adjusted p: N2 = 0.1635; P3 = 0.5248; LPP = 0.5248

no change: Has no effect on behavioral accuracyAccuracy p = 0.7978; reaction time p = 0.7221

Randomized trialacute17 peopleadultsOverweight or obesity; food-related Flanker taskLife (Basel, Switzerland), Nov 14, 2026

down: Decreases fatigue5.1-point reduction in PROMIS Fatigue 7a T-score (95% CI 3.6–6.7)

up: Improves relative peak aerobic capacity+3.1 ml/kg/min (95% CI 2.1–4.0)

Trial12 weeks72 peopleAdvanced prostate cancer receiving ADT-based therapyThe oncologist, Nov 12, 2026

no change: Has no effect on peak oxygen uptakeBaseline-adjusted difference 1.15 mL/kg/min; 95% CI −0.66 to 2.96; P=0.204

no change: Has no effect on serious exercise-related adverse eventsNo serious exercise-related adverse events reported

Randomized trial12 weeks30 peopleClinically stable chronic thromboembolic pulmonary hypertension after balloon pulmonary angioplastyFrontiers in cardiovascular medicine, Nov 10, 2026

no change: Has no effect on subcellular lipid distribution

Trial1.5 hours20 people27.3±1.2 yearsMidlife adults; Endurance-trained athletes under fed and/or fasted conditionsThe Journal of clinical endocrinology and metabolism, Nov 7, 2026

down: Decreases painMean difference −1.24, 95% CI −1.59 to −0.89

up: Increases 6-minute walk distanceMean difference 38.94 m, 95% CI 29.59 to 48.28

down: Decreases depressionBDS mean difference −4.52, 95% CI −6.51 to −2.54

Randomized trial12 weeks48 peopleOsteoporotic vertebral fracturesPhysiotherapy research international : the journal for researchers and clinicians in physical therapy, Nov 7, 2026

down: Decreases CESD-R-20 scoreMean 13.97 to 12.33 points; median 14 to 10 points; scores decreased in 39 participants (59.1%)

Trial66 peopleolder adultsOlder adults; uncontrolled, single-group pre- and post-intervention comparisonRevista Multidisciplinar do Nordeste Mineiro, Nov 4, 2026

down: Decreases blood glucose

no change: Has no effect on daily mean glycemic exposure

up: Increases within-day glycemic variability

Randomized trial8-day protocol29 peopleadultsGeneral population; evening exercise (16:00-19:00) compared with morning exercise (07:00-10:00); normal glucose tolerancebioRxiv, Nov 2, 2026

down: Decreases systolic blood pressureMedian systolic blood pressure: 156.50 to 141.50 mmHg; median diastolic blood pressure: 91.00 to 85.50 mmHg

Trial26 peopleolder adultsOlder adults; hypertension; one-group pretest–posttest comparison without a control groupHealthy Journal, Oct 31, 2026

up: Improves functional mobility

down: Decreases depressive symptoms

up: Improves quality of life

Randomized trialeight weeks40 people60 years and overOlder adults; in older adults with sarcopeniaGeriatric nursing (New York, N.Y.), Oct 31, 2026

up: Improves peak VO2interaction estimate per 10-point increase: 7.30%; 95% CI 0.66–13.94; p=0.032

Randomized trial24 weeks91 peopleBothmedian age 63 years, IQR 57–71Older adults; Midlife adults; modified by baseline healthcare health literacyESC Congress 2026 abstract, Oct 26, 2026

no change: Has no effect on coronary microvascular function

up: Increases flow-mediated vasodilation

Randomized trial12 months21 peoplePrevious myocardial infarction; intervention and control groups merged for baseline-to-follow-up analysisESC Congress 2026 abstract, Oct 26, 2026

up: Improves grip strength+3.1 kg from baseline; 28.9→32.0 kg

down: Decreases frailtyFrailty score −0.40 from baseline; 1.63→1.23

up: Improves cognitive functionK-MMSE +0.81 from baseline; 27.98→28.79

Randomized trial6 months100 peopleChronic heart failureESC Congress 2026 abstract, Oct 26, 2026

no change: Has no effect on fasting glucose

no change: Has no effect on inflammatory markers

Randomized trial24-36 weeks of gestation263 peopleWomenPregnancy with obesitymedRxiv, Oct 24, 2026

up: Improves functional capacity+33 to +73 m in all participants

up: Increases grip strengthRight hand: +0.5 to +5.5 kg in all patients; left hand: +2.0 to +3.5 kg in three patients

up: Improves quality of lifeSeveral domains improved in most participants

Treated cohort12 weeks5 peopleWomenEstablished cancer cachexia; uncontrolled baseline-to-post-intervention comparisonHealthcare (Basel, Switzerland), Oct 23, 2026

up: Improves short Physical Performance Battery scoremean between-group difference of − 2.74 points (95% CI − 4.21 to − 1.27), Cohen's d = 0.68

no change: Has no effect on time to first bowel movement

no change: Has no effect on postoperative complications

Randomized trialpostoperative days 1, 3, and 531 peoplePatients undergoing elective colorectal surgeryPerioperative medicine (London, England), Oct 16, 2026

up: Improves chemotherapy-induced peripheral neuropathy symptomsp < 0.001

Trial10-week36 peopleBothmedian age: 59Cancer survivors experiencing CIPN symptoms ≥6 months post-chemotherapyCurrent oncology (Toronto, Ont.), Oct 15, 2026

up: Improves cognitive functionGood cognitive function: 0% pretest versus 70% posttest; reported scores 4.608±0.499 pretest versus 4.260±0.499 posttest

Trial50 peopleolder adultsOlder adults; uncontrolled pretest–posttest comparisonInternational Journal of Drug Delivery Technology, Oct 15, 2026

up: Improves muscle strength+11.7%

up: Improves functional performance+8.3%

down: Decreases anxiety

Trial14 weeks16 people16 women51.31 ± 9.17 years, range 31 to 66Patient cohortsResearch Square, Oct 14, 2026

no change: Has no effect on intrahepatic fat fraction−0.8 percentage points versus usual care; 95% CI −2.4 to 0.8; P = 0.54

Randomized trial12 weeks187 peopleBothadultsObesityNature communications, Oct 14, 2026

no change: Has no effect on muscle fiber size

no change: Has no effect on skeletal muscle fibrosis

down: Decreases fibro-adipogenic progenitor abundance

Randomized trial12 weeks19 peopleStage 3-5 chronic kidney diseaseAmerican journal of physiology. Renal physiology, Oct 7, 2026

down: Decreases brachial-ankle pulse wave velocity

up: Increases flow-mediated dilation

down: Decreases heart rate variability

Randomized trial17 peopleMenMen with elevated BPClinical physiology and functional imaging, Oct 5, 2026

up: Improves sleep qualityβ = −0.31

Randomized trial12 weeks48 peopleprimarily male (92%)67.5 years old (SD = 3.6)Older veterans with PTSDMental health and physical activity, Oct 1, 2026

down: Decreases systolic blood pressure142.00 ± 18.13 to 132.33 ± 19.96 mmHg, P=0.007

no change: Has no effect on timed Up and Go test6.05 ± 1.00 to 5.84 ± 0.81 seconds, P=0.066

no change: Has no effect on grip strength

Trialaverage period of 10.0 ± 4.1 months9 peoplemean age of 68.1 ± 6.7 yearsCommunity-dwelling older adultsJournal of rural medicine : JRM, Oct 1, 2026

up: Improves individualized goals96.2%

Trialmedian 5.5 days (IQR, 1.5–11.75)26 people57.7% were malemedian age 52.5 years (IQR, 43.3–62.8)Adult inpatients admitted to general wards with at least 48 hours of hospitalization, clinically stable, functionally independent, and without prior physiotherapy referralPhysiotherapy research international : the journal for researchers and clinicians in physical therapy, Oct 1, 2026

down: Decreases frailty43.5% classified as nonfrail after intervention

Trial12 weeks46 peopleBoth68.83 yearsOlder adults; initially frail or prefrail older adultsArchivos en Medicina Familiar, Oct 1, 2026

up: Improves balance

Trial12 weeks60 people55–65 yearsMidlife adults; Older adultsSport Mont, Oct 1, 2026

up: Improves 30-second chair stand test performance17.9±3.5 to 23.7±4.5 reps (control), 18.3±4.0 to 26.6±4.8 reps (experimental)

up: Improves timed Up and Go performance5.6±0.9 to 4.8±0.8 s (control), 5.6±0.8 to 5.0±0.5 s (experimental)

Trial8-week26 peopleWomen66.8±4.8 yearsOlder adultsSport Mont, Oct 1, 2026

down: Lowers the risk of postoperative complications18% vs 48%, OR 0.34 (95% CI 0.13-0.92)

up: Improves exercise tolerance

down: Decreases NT-proBNP

Randomized trial14-18 days80 peopleIn frail patients undergoing coronary artery bypass graftingBulletin of Siberian Medicine, Oct 1, 2026

up: Improves EQ-5D indexmean paired difference = 0.07

up: Improves sit-to-stand performancemean paired difference = 2.98

up: Increases average daily step countmean paired difference = 638

TrialMedian duration of participation in TEC was 9 months168 peoplemenmean (SD) age of 70.6 years (7.8)Patients receiving treatment for prostate cancerBJUI compass, Sep 30, 2026

up: Improves functional outcomes

Randomized trial310 peopleBothaverage age 87 yearsThe oldest old; Older adults; during acute hospitalizationEuropean geriatric medicine, Sep 30, 2026

no change: Has no effect on processing speed

up: Increases moderate to vigorous physical activityb = 4.33 minutes/day, P <.01

up: Improves attentionb = 0.14, P = 0.03

Randomized trial6-month physical activity intervention, with 6 months of maintenance support253 peoplefemaleaverage 58.5 years old, ranging from 40 to 82 years oldFemale breast cancer survivorsJournal of the National Cancer Institute, Sep 30, 2026

down: Decreases GrimAge2

down: Decreases DNAmFitAge

Randomized trial12-month124 peopleWomenon average 58.8 years oldSedentary breast cancer survivors within 5 years of diagnosisJournal of the National Cancer Institute, Sep 30, 2026

up: Increases 2-Minute Walk Test distanceT2 versus T1: 5.00 m (95% CI: -0.29 to 10.29); mixed-model p = 0.063; paired comparison p = 0.046

no change: Has no effect on exercise-testing outcomesNumerical increases were not statistically significant

Trial12 weeks20 peopleadultsMultiple sclerosis; uncontrolled within-group comparisonLife (Basel, Switzerland), Sep 29, 2026

down: Decreases systolic blood pressure-4.6 mmHg (95% CI: 2.36-6.84)

down: Decreases diastolic blood pressure-2.4 mmHg (95% CI: 0.53-3.27)

down: Decreases perceived stress-2.5 points (95% CI: 1.87-4.67)

Randomized trial12 weeks27 peopleGeneral populationActa psychologica, Sep 29, 2026

up: Improves strength

Randomized trial12 weeks24 peopleBothmean age 53Patient cohorts; Midlife adultsTopics in spinal cord injury rehabilitation, Sep 28, 2026

up: Increases peak oxygen consumptionB = 2.12

up: Increases anaerobic thresholdB = 1.83

up: Improves gait speedB = 0.07

Randomized trial12 weeks120 people20–80 yearsParticipants aged 20–80 years with long COVIDResearch Square, Sep 25, 2026

up: Improves freezing of gait questionnaireSMD -0.62, 95% CI -1.06 to -0.18

up: Improves Unified Parkinson's Disease Rating Scale Part IIISMD -0.80, 95% CI -1.02 to -0.59

up: Improves berg Balance ScaleSMD 0.85, 95% CI 0.27 to 1.42

Review of trials714 people pooledPatients with PDPloS one, Sep 25, 2026

up: Increases CD8+ TEMRA cellsHedges’ g = 1.26

down: Decreases CD8+ naive T cellsHedges’ g = − 1.16

down: Prevents insulin

Trial12-week11 peoplewomen49.1 ± 14.4 yearsPatients with histologically confirmed breast cancer undergoing (neo)adjuvant chemotherapy (± immunotherapy)Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, Sep 24, 2026

down: Decreases being told they had poor memoryOR 0.61, 95% CI 0.38 to 0.98

up: Improves ability to shop for food or other necessitiesOR 1.53, 95% CI 1.07 to 2.20

no change: Has no effect on proportion of daily activities performedOR 0.96, 95% CI 0.69 to 1.33

Randomized trialapproximately 2 weeks before surgery and continuing for 4 weeks after discharge761 people39% were womenmedian age of 70 yearsPatients aged 20 years or older with colorectal cancer scheduled to undergo elective surgery with curative intentBMJ open, Sep 23, 2026